Selected Presentations
Swiss Day of Laboratory Medicine
Bern, Switzerland / November 03, 2023
M. Schlander, R. Schäfer, L. Selberg (2023):
Nutzen der Labormedizin in der Schweiz
(Value of Laboratory Medicine in Switzerland).
18th International EBHC Symposium
Krakow, Poland / October 08-09, 2023
M. Schlander (2023):
Health Technology Assessment: Changing Perspectives on Value (& Valuation).
Health Technology Assessment international (HTAi) Global Policy Forum
The Hague, The Netherlands / March 27, 2023
A. Morton, M. Schlander (2023):
Debate - Value and Impact of HTA: "Are Our Current Ways to Conduct HTAs Fit For Purpose?"
6th Swiss Healthcare Day
Bern, Switzerland / January 15, 2020
M. Schlander (2020):
WZW & HTA. Wie steht es um die Kosten- / Nutzen-Beurteilung in der Schweiz?
(WZW & HTA. How about Cost-Benefit Assessment in Switzerland?)
19th Annual European Congress of the International Society for Health Economics and Outcomes Research (ISPOR)
Vienna, Austria / October 29 - November 02, 2016
R. Schaefer, M. Schlander (2016):
Different Methods, Different Results? Comparing Health Technology Assessments in the United Kingdom and Germany.
Value in Health 2016; 19(7): A494
EURORDIS Roundtable of Companies (ERTC) Meeting: Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies
Brussels, Belgium / February 24, 2016
M. Schlander (2016):
The Social Value of Orphan Medicinal Products (OMPs): European Social Preferences Measurement (ESPM) Study Project.
Health Economics Global Congress
London, United Kingdom / December 07, 2015
M. Schlander (2015):
"The Burning Platform" - Credibility of Corporate Health Economics.
ISPOR 20th Annual International Meeting
Philadelphia, PA, USA / May 16-20, 2015
M. Schlander (2015):
The Controversial Role of Cost-Effectiveness Analyses (CEA) and Incremental Cost-Effectiveness Ratio (ICER) Thresholds in Value-Based Assessments (VBA) of Health Technologies: What are the Future Challenges?
11th HTAi Annual Meeting
Washington, DC, USA / June 15-18, 2014
M. Schlander, C. Affolter, T.B. Cueni, H. Sandmeier for the SwissHTA Group (2014):
Health Technology Assessment (HTA) in Switzerland: The “SwissHTA” Multi-Stakeholder Consensus.
ISPOR 16th Annual European Congress
Dublin, Ireland / November 2-6, 2013
M. Schlander, M.A. Khan, A. Iezzi, A. Maxwell, O. Schwarz, J. Richardson (2013):
The Measurement of Health-Related Quality of Life: German Findings from the Multi-Instrument Comparison (MIC) Study.
Value in Health 2013; 16(7): A330
9th European Congress of Health Economics (ECHE)
Zurich, Switzerland / July 18-21, 2012
M. Schlander (2012):
Will Progress in Applied Health Economics Depend on a New Evaluation Paradigm?
ISPOR 14th Annual European Congress
Madrid, Spain / November 5-8, 2011
M. Schlander, A. Philipsen, O. Schwarz, and the COMPAS Study Group (2011):
The Cost Effectiveness of Clinically Proven Treatment Strategies for ADHD in Adult Patients.
Value in Health 2011; 14(7): A403
Verein für Socialpolitik, Ausschuss für Gesundheitsökonomie
Augsburg, Germany / October 16, 2010
M. Schlander, M.A. Khan, J. McKie, J. Richardson (2010):
Health-Realted Quality of Life (HRQoL) Instruments: Some Prerequisites for Their Appropriate Use in Economic Evaluation.
ISPOR 13th Annual International Meeting
Toronto, ON, Canada / May 3-7, 2008
M. Schlander (2008):
Issues Panel, "QALYs Gone Wild?", Over-Reliance on QALYs may Contribute to the Neglect of Relevant Evidence.
13th International Congress of the European Society for Child and Adolescent Psychiatry (ESCAP)
Florence, Italy / August 25-29, 2007
M. Schlander (2007):
Cost-Effectiveness of ADHD Treatment Strategies: What We Do Know... and What We Do Not Know....
ISPOR 9th Annual European Congress
Copenhagen, Denmark / October 29-31, 2006
M. Schlander, O. Schwarz, L. Hakkaart-van Roijen, P.S. Jensen, U. Persson, P. Santosh, G.-E. Trott, and the MTA Cooperative Group (2006):
Cost-Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States, Germany, The Netherlands, Sweden, and United Kingdom.
Value in Health 2006; 9(6): A312